Advancing Alternative BBB Shuttle Platforms Through Antibody Discovery Structural Biology & Imaging Validation

• Designing novel receptor mediated transcytosis shuttles to expand CNS delivery beyond transferrin based systems
• Linking antibody affinity epitope binding and intracellular trafficking to optimize brain exposure and release
• Integrating antibody discovery datasets with structural biology to improve shuttle performance
• Using brain imaging approaches to quantify distribution and validate delivery efficiency across regions

Speakers:

Allan Jensen

Vice President, Biotherapeutic Discovery

Lundbeck